The Parker Institute for Cancer Immunotherapy has invested in a chimeric antigen receptor T cell technology developed by Xyphos Biosciences Inc of South San Francisco, US which claims the platform is safer and more effective than existing approaches. Financial terms of the collaboration were not disclosed.
